StockData
GeoVax Labs, Inc. logo

GeoVax Labs, Inc. (GOVX) stock

GOVXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$0.23−0.01 (-4.53%)

Close on Oct 19, 2026Market cap $1.04MP/E –Yield –

GeoVax Labs free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

GeoVax Labs's free cash flow for the twelve months ending Jun 30, 2026 was -$18.37M. For fiscal 2025 it was -$21.50M. The highest annual figure on record is -$315.52K in fiscal 2011.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$21.50M–
FY2024Dec 31, 2024-$24.70M–
FY2023Dec 31, 2023-$25.22M–
FY2022Dec 31, 2022-$19.16M–
FY2021Dec 31, 2021-$11.24M–
FY2020Dec 31, 2020-$2.91M–
FY2019Dec 31, 2019-$1.41M–
FY2017Dec 31, 2017-$1.69M–
FY2015Dec 31, 2015-$2.72M–
FY2014Dec 31, 2014-$2.29M–
FY2013Dec 31, 2013-$1.78M–
FY2011Dec 31, 2011-$315.52K–
FY2010Dec 31, 2010-$2.44M–
FY2009Dec 31, 2009-$1.70M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.66M–
Q1 FY2026Mar 31, 2026-$3.54M–
Q4 FY2025Dec 31, 2025-$4.96M–
Q3 FY2025Sep 30, 2025-$6.21M–
Q2 FY2025Jun 30, 2025-$4.35M–
Q1 FY2025Mar 31, 2025-$5.98M–
Q4 FY2024Dec 31, 2024-$7.75M–
Q3 FY2024Sep 30, 2024-$9.32M–
Q2 FY2024Jun 30, 2024-$1.94M–
Q1 FY2024Mar 31, 2024-$5.68M–
Q4 FY2023Dec 31, 2023-$10.30M–
Q3 FY2023Sep 30, 2023-$5.10M–
Q2 FY2023Jun 30, 2023-$6.06M–
Q1 FY2023Mar 31, 2023-$3.76M–
Q4 FY2022Dec 31, 2022-$7.06M–
Q3 FY2022Sep 30, 2022-$3.85M–
Q2 FY2022Jun 30, 2022-$3.85M–
Q1 FY2022Mar 31, 2022-$4.40M–
Q4 FY2021Dec 31, 2021-$6.68M–
Q3 FY2021Sep 30, 2021-$1.66M–
Q2 FY2021Jun 30, 2021-$1.28M–
Q1 FY2021Mar 31, 2021-$1.62M–
Q4 FY2020Dec 31, 2020-$1.70M–
Q3 FY2020Sep 30, 2020-$285.60K–
Q4 FY2019Dec 31, 2019-$284.09K–
Q3 FY2019Sep 30, 2019-$343.93K–
Q2 FY2019Jun 30, 2019-$456.45K–
Q1 FY2019Mar 31, 2019-$321.63K–
Q4 FY2017Dec 31, 2017-$448.44K–
Q3 FY2017Sep 30, 2017-$478.77K–
Q2 FY2017Jun 30, 2017-$429.15K–
Q1 FY2017Mar 31, 2017-$336.45K–

More GeoVax Labs figures

See a number that looks wrong?